{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:01:36Z","timestamp":1784890896560,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Interleukin-17 receptor A (IL17RA) acts as a core mediator of pro-inflammatory signaling and contributes crucially to the pathogenesis of autoimmune disorders including psoriasis and rheumatoid arthritis. Monoclonal antibodies against IL17RA have achieved clinical application, yet their clinical utility is restricted by multiple drawbacks: high production cost, complicated manufacturing procedures, mandatory injection delivery, and absent oral bioavailability. To overcome these bottlenecks, this study develops a novel inhibitory peptide WMX-8 intended to specifically disrupt the binding between IL17A and IL17RA. The polypeptide WMX-8 was rationally designed and chemically synthesized, followed by purification to obtain high-purity samples. A series of systematic in vitro biological assessments were conducted using IL17RA-expressing cell models (keratinocytes and monocyte-macrophages), alongside IL17RA-deficient cells as negative control groups. Biochemical and cellular assays verified that WMX-8 binds IL17RA with strong affinity and markedly suppresses the secretion of pro-inflammatory cytokines in IL17RA-positive keratinocytes and monocyte-macrophages. Its anti-inflammatory efficacy is equivalent to that of the reference anti-IL17RA monoclonal antibody. The inhibitory activity fully relies on IL17RA expression, since the anti-inflammatory effect disappears entirely in IL17RA-knockout cells. In addition, WMX-8 displays desirable pharmaceutical features, including low immunogenicity and convenient large-scale synthesis.This study validates the promising druggable properties of WMX-8 targeting the IL17A\u2013IL17RA axis. Our findings lay a solid foundation for further preclinical investigation of peptide therapeutics against IL17A\/IL17RA for the treatment of autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fphar.2026.1842752","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:14:07Z","timestamp":1784888047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-inflammatory effect of novel polypeptide WMX-8 through specific blockade of the IL17RA signaling pathway"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinmin","family":"Wang","sequence":"first","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Bao","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Wang","sequence":"additional","affiliation":[{"name":"Inner Mongolia Autonomous Region People\u2019s Hospital","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalu","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbin","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Inner Mongolia University of Science and Technology","place":["Baotou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","first-page":"1687","article-title":"IL-17A induces pro-inflammatory cytokines production in macrophages via MAPKinases, NF-\u03baB and AP-1","volume":"8","author":"Chen","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"B2","first-page":"1600668","article-title":"A truncated IL-17RC peptide ameliorates synovitis and bone destruction in collagen-induced arthritis mice","volume":"6","author":"Du","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"B3","first-page":"3456","article-title":"Off-label use and expanded indications of IL-17 pathway inhibitors","volume":"11","author":"Fotiadou","year":"2022","journal-title":"J. Clin. Med."},{"key":"B4","first-page":"45","article-title":"Preclinical evaluation of synthetic peptides for the treatment of collagen-induced arthritis","volume":"29","author":"Liu","year":"2023","journal-title":"Int. J. Peptide Res. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J. Inflammation Research"},{"key":"B7","doi-asserted-by":"publisher","first-page":"26071","DOI":"10.1038\/srep26071","article-title":"Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Reports"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1608909","DOI":"10.3389\/fimmu.2025.1608909","article-title":"Therapeutic mechanisms of polysaccharides in the management of rheumatoid arthritis: a comprehensive review","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.immuni.2023.06.012","article-title":"An autonomous activation of interleukin-17 receptor signal sustains inflammation and disease progression","volume":"56","author":"Luo","year":"2023","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3390\/pathogens12091156","article-title":"Impact of treatment with ustekinumab on severe infections in a patient with uncontrolled psoriasis and late-onset combined primary immunodeficiency: case report","volume":"12","author":"Prestes-Carneiro","year":"2023","journal-title":"Pathogens"},{"key":"B12","first-page":"21","article-title":"Immunogenicity of anti-IL-17 monoclonal antibodies in chronic inflammatory disorders","volume":"32","author":"Reich","year":"2018","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09546634.2020.1744505","article-title":"An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan","volume":"33","author":"Saeki","year":"2022","journal-title":"J. Dermatological Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40259-024-00687-w","article-title":"Interleukin-17 inhibitors in the treatment of hidradenitis suppurativa","volume":"39","author":"Salgueiro","year":"2024","journal-title":"BioDrugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1039\/d3sc00728f","article-title":"Modulation of IL-17 backbone dynamics reduces receptor affinity and reveals a new inhibitory mechanism","volume":"14","author":"Shaw","year":"2023","journal-title":"Chem. Sci."},{"key":"B16","first-page":"1201","article-title":"Structural basis of peptide ligands targeting the IL-17 cytokine family","volume":"77","author":"Sun","year":"2021","journal-title":"Acta Crystallogr. Sect. D."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0190850","DOI":"10.1371\/journal.pone.0190850","article-title":"Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discovery","volume":"13","author":"Ting","year":"2018","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8542","DOI":"10.1038\/s41598-025-92915-8","article-title":"Innovative peptide therapeutics targeting IL17RA to regulate inflammatory responses","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"B20","first-page":"103289","article-title":"Peptide therapeutics for autoimmune inflammatory diseases: progress and challenges","volume":"141","author":"Yen","year":"2025","journal-title":"J. Autoimmun."},{"key":"B21","first-page":"8342","article-title":"IL-17A promotes migration of macrophages and synoviocytes via IL-17RA in CIA models","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3390\/molecules28041806","article-title":"An Interleukin-17 isoform from thick shell mussel Mytilus coruscus serves as a mediator of inflammatory response","volume":"28","author":"Zhao","year":"2023","journal-title":"Molecules"},{"key":"B24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12906-024-04397-2","article-title":"IL-17\/IL-17RA axis regulates MMP-9 expression and synovial damage in rheumatoid arthritis","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Complementary Med. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:14:09Z","timestamp":1784888049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1842752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":24,"alternative-id":["10.3389\/fphar.2026.1842752"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1842752","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1842752"}}